Ranjit K. Harwansh*, Shiv Bahadur, Rohitas Deshmukh and Md. A. Rahman Pages 1191 - 1205 ( 15 )
Breast cancer (BC) is a multifactorial disease and becoming a major health issue in women throughout the globe. BC is a malignant type of cancer which results from transcriptional changes in proteins and genes. Besides the availability of modern medicines and detection tools, BC has become a topmost deadly disease and its cure still remains challenging. Nanotechnology based approaches are being employed for the diagnosis and treatment of BC at clinical stages. Nanosystems have a significant role in the study of the interaction of malignant cells with their microenvironment through receptor-based targeted approach. Nowadays, lipid-based nanocarriers are being popularized in the domain of pharmaceutical and medical biology for cancer therapy. Lipidic nanoparticlized systems (LNPs) have proven to have high loading efficiency, less toxicity, improved therapeutic efficacy, enhanced bioavailability and stability of the bioactive compounds compared to traditional drug delivery systems. In the present context, several LNPs based formulations have been undertaken in various phases of clinical trials in different countries. This review highlights the importance of chemotherapeutics based lipidic nanocarriers and their anticipated use for the treatment of BC. Furthermore, the clinical trials and future prospective of LNPs have been widely elaborated.
Lipidic nanoparticlized system, nanocarriers, nanoparticles, breast cancer, clinical trials, bioactive compunds.
Institute of Pharmaceutical Research, GLA University, Mathura - 281406, Institute of Pharmaceutical Research, GLA University, Mathura - 281406, Institute of Pharmaceutical Research, GLA University, Mathura - 281406, College of Pharmacy, Taif University, Taif - 21974